Thermo Fisher Scientific Q4 2025 Earnings Analysis

**BETA FINCH PODCAST SCRIPT**---**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into Thermo Fisher Scientific's Q4 2025 results. Before we get started, I want to remind everyone that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN:** Thanks Alex. And what a quarter to analyze! Thermo Fisher just delivered some really solid numbers to cap off 2025, plus they dropped a massive $9 billion acquisition announcement. There's a lot to unpack here.**ALEX:** Absolutely. Let's start with the headline numbers, Jordan. Q4 revenue came in at $12.21 billion, up 7% year-over-year. For the full year, they hit $44.56 billion in revenue, growing 4%. But here's what I found interesting - their adjusted EPS grew 8% in the quarter to $6.57, and 5% for the full year to $22.87.**JORDAN:** That EPS growth is noteworthy because it shows they're managing their operations really well despite some headwinds. CEO Marc Casper mentioned they faced over 100 basis points of margin pressure from tariffs and foreign exchange impacts. Yet they still delivered solid earnings growth - that's the power of their PPI business system at work.**ALEX:** Speaking of headwinds, let's talk about how different end markets performed. Pharma and biotech was the standout - high single-digit growth in Q4 and mid-single digits for the full year. That's their core market, so seeing strength there is crucial.**JORDAN:** Right, and Casper gave some really interesting color on customer sentiment in pharma during the Q&A. He talked about meeting with pharma CEOs who were much more optimistic, saying the tone in January customer meetings was "quite positive." He even shared this great anecdote about a pharma CEO who was so engaged in their discussion that he literally went and found his head of development mid-conversation to dive deeper into specifics.**ALEX:** That's the kind of customer relationship that's hard to quantify but incredibly valuable. It speaks to their "trusted partner" positioning. But not all end markets were as rosy - academic and government declined low single digits both for the quarter and full year, largely due to macro conditions in the US and China.**JORDAN:** Yeah, and that's reflected in their 2026 guidance assumptions. They're basically planning for similar market conditions to 2025, which seems prudent. They're guiding for 3-4% organic growth and 4-6% reported revenue growth, targeting $46.3 to $47.2 billion in revenue.**ALEX:** The earnings guidance is where things get interesting though. They're projecting 6-8% adjusted EPS growth, hitting $24.22 to $24.80 per share. That's pretty strong earnings leverage even with modest revenue growth.**JORDAN:** Exactly, and that doesn't even include the potential impact from their big acquisition announcement - Clario. This is a $9 billion deal for a digital endpoint data provider that generated about $1.5 billion in 2025 revenue. If it closes by year-end as expected, it could add another $0.45 in adjusted EPS.**ALEX:** Let's dig into that Clario deal because it's fascinating strategically. They're essentially buying capabilities in one of the fastest-growing areas of clinical research - digital endpoints for clinical trials. This fits perfectly with their "Accelerated Drug Development" solution that combines their pharma services and clinical research businesses.**JORDAN:** And Casper was really enthusiastic about this during the call. He talked about how it will enable "even deeper clinical insights" and "further accelerate the digital transformation of clinical research." Plus, they mentioned it has an attractive double-digit return profile and will be accretive to both organic growth and margins.**ALThis episode includes AI-generated content.